

- Gasser HS. Changes in nerve-potentials produced by rapidly repeated stimuli and their relation to the responsiveness of nerve to stimulation. *Am J Physiol* 1935;111:35–50.
- Gordon TR, Kocsis JD, Waxman SG. Electrogenic pump ( $\text{Na}^+/\text{K}^+$ -ATPase) activity in rat optic nerve. *Neuroscience* 1990;37:829–37.
- Inglis JT, Leeper JB, Wilson LR, Gandevia SC, Burke D. The development of conduction block in single human axons following a focal nerve injury. *J Physiol* 1998;513:127–33.
- Kaji R, Bostock H, Kohara N, Murase N, Kimura J, Shibasaki H. Activity-dependent conduction block in multifocal motor neuropathy. *Brain* 2000;123:1602–11.
- Kiernan MC, Lin CS, Burke D. Differences in activity-dependent hyperpolarization in human sensory and motor axons. *J Physiol* 2004;558:341–9.
- Kuwabara S, Lin CS, Mogyoros I, Cappelen-Smith C, Burke D. Voluntary contraction impairs the refractory period of transmission in healthy human axons. *J Physiol* 2001;531:265–75.
- Kuwabara S, Cappelen-Smith C, Lin CS, Mogyoros I, Burke D. Effects of voluntary activity on the excitability of motor axons in the peroneal nerve. *Muscle Nerve* 2002;25:176–84.
- Lin CS, Mogyoros I, Kuwabara S, Cappelen-Smith C, Burke D. Accommodation to depolarizing and hyperpolarizing currents in cutaneous afferents of the human median and sural nerves. *J Physiol* 2000;529(pt2):483–92.
- Sanders DB, Stålberg EV. AAEM minimonograph #25: single-fiber electromyography. *Muscle Nerve* 1996;19:1069–83.
- Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). *Biometrika* 1965;52:591–611.
- Stålberg E. Propagation velocity in human muscle fibers in situ. *Acta Physiol Scand Suppl* 1966;287:1–112.
- Stålberg E, Trontelj JV, Mihelin M. Electrical microstimulation with single-fiber electromyography: a useful method to study the physiology of the motor unit. *J Clin Neurophysiol* 1992;9:105–19.
- Trontelj JV, Mihelin M, Fernandez JM, Stålberg E. Axonal stimulation for end-plate jitter studies. *J Neurol Neurosurg Psychiatry* 1986;49:677–85.
- Vagg R, Mogyoros I, Kiernan MC, Burke D. Activity-dependent hyperpolarization of human motor axons produced by natural activity. *J Physiol* 1998;507:919–25.
- Westfall PH, Young SS. Resampling-based multiple testing. New York: Wiley; 1993.

## Inactivation of the putamen selectively impairs reward history-based action selection

Manabu Muranishi · Hitoshi Inokawa ·  
Hiroshi Yamada · Yasumasa Ueda · Naoyuki Matsumoto ·  
Masanori Nakagawa · Minoru Kimura

Received: 13 September 2010 / Accepted: 29 December 2010 / Published online: 6 February 2011  
© The Author(s) 2011. This article is published with open access at Springerlink.com

**Abstract** Behavioral decisions and actions are directed to achieve specific goals and to obtain rewards and escape punishments. Previous studies involving the recording of neuronal activity suggest the involvement of the cerebral cortex, basal ganglia, and midbrain dopamine system in these processes. The value signal of the action options is represented in the striatum, updated by reward prediction errors, and used for selecting higher-value actions. However, it remains unclear whether dysfunction of the striatum leads to impairment of value-based action selection. The present study examined the effect of inactivation of the putamen via local injection of the GABA<sub>A</sub> receptor agonist

muscimol in monkeys engaged in a manual reward-based multi-step choice task. The monkeys first searched a reward target from three alternatives, based on the previous one or two choices and their outcomes, and obtained a large reward; they then earned an additional reward by choosing the last rewarded target. Inactivation of the putamen impaired the ability of monkeys to make optimal choices during third trial in which they were required to choose a target different from those selected in the two previous trials by updating the values of the three options. The monkeys normally changed options if the last choice resulted in small reward (lose-shift) and stayed with the last choice if it resulted in large reward (win-stay). Task start time and movement time during individual trials became longer after putamen inactivation. But monkeys could control the motivation level depending on the reward value of individual trial types before and after putamen inactivation. These results support a view that the putamen is involved selectively and critically in neuronal circuits for reward history-based action selection.

**Keywords** Putamen · Muscimol · Reward · Reinforcement learning · Decision-making

---

Manabu Muranishi and Hitoshi Inokawa contributed equally to this work.

---

M. Muranishi (✉) · H. Inokawa · H. Yamada · Y. Ueda ·  
N. Matsumoto · M. Kimura (✉)  
Department of Neurophysiology, Kyoto Prefectural University  
of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku,  
Kyoto 602-8566, Japan  
e-mail: muranishi.manabu@jp.panasonic.com

M. Kimura  
e-mail: mkimura@lab.tamagawa.ac.jp

M. Nakagawa  
Department of Neurology, Kyoto Prefectural University  
of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku,  
Kyoto 602-8566, Japan

H. Yamada  
Center for Neural Science, New York University,  
New York, NY, USA

M. Kimura  
Brain Science Institute, 6-1-1,  
Tamagawa Gakuen, Machida, Tokyo 194-8610, Japan

### Introduction

Fundamental to decision-making is the ability to use past experience to select the best course of action among competing alternatives. In reinforcement learning theories, the problem of finding an optimal action in an uncertain environment is solved based on value functions representing the expected sum of future rewards for particular states or actions (Sutton and Barto 1998). The striatum is known as a key site involved in multiple cortico-basal

ganglia loop circuits including the motor loop through the putamen, oculomotor loop through the caudate nucleus, anterior cingulate loop through the ventral striatum (Alexander et al. 1986; Middleton and Strick 2000). The basal ganglia systems have been suggested to play a major role in action (DeLong et al. 1986; Desmurget and Turner 2008; Nambu 2008), purposeful behavior (Hikosaka et al. 2000; Kimura et al. 2004), and habit learning (Graybiel 2008; Tricomi et al. 2009; Ashby et al. 2010) through the integration of specific cortical inputs and dopaminergic modulatory inputs. In addition, a growing body of evidence suggests that the striatum adaptively encodes values of action options (action value) (Samejima et al. 2005; Hikosaka et al. 2006; Lau and Glimcher 2008) and of chosen actions (chosen value) (Pasquereau et al. 2007; Lau and Glimcher 2008). The encoded values are updated by reward prediction error signals provided by midbrain dopaminergic neurons (Schultz et al. 1997; Hollerman et al. 1998; Fiorillo et al. 2003; Satoh et al. 2003; Morris et al. 2004). In the reinforcement learning model of the basal ganglia, the value signals are mediated by the striatum (Houk et al. 1995; O'Doherty et al. 2004), whereas the cortico-basal ganglia loops mediate the comparison of values of action (Doya 2000). Specific involvement of the dorsal and ventral striatum in goal-directed and habitual responding (Balleine and O'Doherty 2010; Corbit and Janak 2010) and update of responding by outcomes (Ito and Doya 2009) have also been reported in rodents. However, it is still unknown how the value representation in the striatum contributes to action selection.

In the present study, we addressed this issue by blocking neuronal activity in the putamen via local injection of the GABA<sub>A</sub> receptor agonist muscimol into the putamen of monkeys engaged in a reinforcement-based multi-step choice task. The monkeys first searched for a target from three alternatives based on the histories of the last choices and their outcomes and obtained water as a reward (search epoch); they then could earn an additional reward by choosing the last rewarded target again on the basis of positive reinforcers (repetition epoch). After the putamen was inactivated locally by muscimol, the monkeys not only changed options if the last choice resulted in no reward (lose-shift) but also stayed with the last choice if it was rewarded (win-stay) normally. However, the rate of non-optimal choices increased at the third trial following two successive no reward choices where the monkeys chose an option already tried at the first choice. To make an optimal choice at the third trials, it was necessary for the monkeys to update values of individual options based on the previously tried two options and their outcomes and to choose highest-value options. Therefore, the specific effects of inactivation suggested pivotal roles of the putamen in reward history-based value update and action selection. Although the

motivation to work for reward may have declined because the time from the start cue to the initiation of trials increased, monkeys could control the motivation level depending on the reward value of individual trial types similar to the choices before putamen inactivation.


## Materials and methods

### Animals and surgery

Two female Japanese monkeys (*Macaca fuscata*; monkey TN, 5.8 kg and monkey YO, 6.0 kg) were used. All surgical and experimental procedures were approved by the Animal Care and Use Committee of Kyoto Prefectural University of Medicine and were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Four head-restraining bolts and one stainless-steel recording chamber were implanted on the monkey's skull using standard surgical procedures. The monkeys were sedated with ketamine hydrochloride (10 mg/kg, i.m.) and then anesthetized with sodium pentobarbital (Nembutal; 27.5 mg/kg, i.p.). Supplemental Nembutal (10 mg/kg, 2 h, i.m.) was given as needed. A rectangular chamber (25 × 37 × 20 mm) was positioned on the left cerebral cortex at an angle of 45° under stereotaxic guidance to monitor the activity of putamen neurons and to insert the needle for injection of muscimol, as described below.

### Behavioral task

To study how the putamen is involved in value- and task-strategy-based action selection, we employed a behavioral task for monkeys to make multi-step choices of one target from three alternatives for rewards. The monkeys were trained to sit in a primate chair facing a small panel placed 21 cm in front of their faces. Five LEDs were embedded on the panel: a small rectangular start button with a green light-emitting diode (LED) (start LED, 14 × 14 mm) at the bottom, 3 target buttons with green LEDs (target LEDs, 14 × 14 mm) in the middle row, and a small red LED (GO LED, 4 mm diameter) just above the center push buttons (Fig. 1a). Individual trials were initiated by illumination of the start LED. The monkeys depressed the illuminated start button with their right hand. When the monkeys continued to hold the button for 800 ms, the start LED was turned off and three target LEDs and a GO LED turned on simultaneously. The GO LED turned off, if the monkeys kept depressing the start button for another 50 ms. They then released the start button and depressed one of 3 illuminated target buttons (N1 trials). One of the 3 targets was associated with large reward, while the other 2 were



**Fig. 1** Behavioral task and performance. **a** Illustration of sensorimotor events that occurred during single trials. TST, RTGO, and MT are task start time, reaction time to GO, and the time from release of the start button to depression of the target button, respectively. **b** Trial types during the search epoch and repetition epoch. Gray and white rectangles represent non-rewarded and rewarded trials, respectively.

**c** One block consisted of 12 trials for each trial type, and 6 blocks were performed per day. The first and second blocks were pre-injection blocks, and the third and fourth blocks were post-injection blocks. **d** Average reward probabilities during 4 types of trials in all pre-injection blocks for monkey TN (black line) and monkey YO (broken line). Error bars represent SEM

small-reward targets. If a small-reward button was depressed, a beep sound with a low tone (300 Hz, 100 ms) occurred with a delay of 500 ms, and a small amount of reward water (0.05 ml) was delivered through a spout attached to the monkey’s mouth. If the monkeys chose the small-reward button again in the second trial (N2), the third (N3) trial started after a low-tone beep and a small reward had been presented. If a large-reward button was depressed, a beep sound with a high tone (1 k Hz, 100 ms) occurred with a delay of 500 ms, and a large amount of water (0.25 ml) was delivered. We used separate LEDs for the target on (illuminations of 3 green targets and a small red “pre-GO” signal) and for GO signal (offset of the “pre-GO” LED). Reaction time, from GO signal onset to release of the hold button, measured the time for monkeys to initiate choices after decisions had been made based on the preceding target signal.

The high-tone and low-tone beep sounds served as positive and negative feedback, respectively. Once the monkeys found a large-reward button during the search trials, they could obtain additional rewards by choosing the same button in the following repetition trial (R). The start button and the three target buttons flashed at the same time for 100 ms to inform the animal of the end of a series of trials. The next series of choice trials began at 4.0 s after the flashing of target buttons with the large-reward button appearing at a random target location.

Thus, the trials in a single series of choices were divided into two epochs (Fig. 1b). The first epoch was the search epoch, in which the monkey searched for a large-reward button on a trial-and-error basis. While an optimal strategy was to choose the button not selected in the previous trials (*lose-shift* strategy), this strategy was not sufficient for N3 trials in which monkeys had chosen small-reward buttons during the last two successive trials; i.e., instead, they had to choose the one remaining button, but not the one selected in the N1 or N2 trials. Thus, it was required for monkeys to choose the highest-value option among three alternatives while updating values of individual options based on the history of choices and their outcomes. The second epoch was the repetition epoch in which the monkeys again chose the large-reward button found in the last trials during the search epoch (*win-stay* strategy). One block consisted of at least 12 trials for each trial type. Task performance was studied parametrically during six blocks (2 pre-injection blocks, 2 post-injection blocks, and 2 additional blocks) in a day (Fig. 1c). Although the monkeys consistently performed task after muscimol injection during two post-injection blocks, they sometimes stopped performing the task during subsequent blocks. Therefore, we used 2 blocks of trials for pre-injection data and two additional post-injection blocks of trials (the third and fourth blocks) after muscimol injection as.

## Electrophysiological mapping and muscimol injections

After recovery from surgery, single-unit recordings were made to map the rostral, middle, and caudal parts of the putamen during performance of the behavioral task. We used epoxy-coated tungsten microelectrodes (Frederick Haer Company, Bowdoinham, ME) with an exposed tip of 15  $\mu\text{m}$  and impedances of 2–5  $\text{M}\Omega$  (at 1 kHz). The neuronal activity was amplified and displayed on an oscilloscope using conventional electrophysiological techniques. Bandpass filters (50 Hz–3 kHz bandpass with a 6 dB per octave roll-off) were used. The action potentials of single neurons were isolated by using a spike sorter with a template-matching algorithm (MSD4; Alpha Omega; Nazare), and the duration of negative-going spikes was determined at a resolution of 40  $\mu\text{s}$ . The onset times of the action potentials were recorded on a laboratory computer, together with the onset and offset times of the stimulus and behavioral events that occurred during the behavioral tasks. The electrodes were inserted through the implanted recording chambers and advanced by means of an oil-drive micromanipulator (MO-95; Narishige, Tokyo, Japan). To identify the topographical location of the putamen, we made recordings of multi- and single-unit activity through the course of the cerebral cortex dorsally, then the putamen and the globus pallidus ventrally in the middle and posterior levels of the putamen. These three structures show distinctive patterns of activity, such as very low background firing and infrequently occurring bursting discharges characteristic of striatal projection neurons, tonic-activity and tonically active characteristic of cholinergic interneurons, and very high frequency spikes characteristic of the globus pallidus (Yamada et al. 2004; Hori et al. 2009; Inokawa et al. 2010). For mapping the putamen, recordings were made from 35 locations of electrode penetrations in Monkey TN and from 15 locations in Monkey YO. Following injection of muscimol or saline in the putamen, neuronal spike activity was recorded by using a fine wire electrode (50  $\mu\text{m}$  diameter) attached to the injection cannula to confirm that the injection sites were in the expected locations in the putamen.

The effects of muscimol and saline injections in the putamen on the task were studied after the completion of electrophysiological mapping of the putamen. Based on the effects of muscimol injection on task performance, the injection sites were separated into three parts: anterior level (3 mm anterior to the anterior edge of the anterior commissure, AC), middle level (3 mm posterior to the anterior edge of the AC), and posterior level (4–7 mm posterior to the anterior edge of the AC). The unilateral injections were made in the putamen (left hemisphere) contralateral to the arm used for button selection (right hand). Muscimol (5  $\mu\text{g}/\mu\text{l}$ ) or isotonic saline was injected locally in the putamen through

30-gauge cannula with a beveled tip which was connected by a fine polyethylene tube to a Hamilton syringe (5  $\mu\text{l}$ ). The injection speed was 0.25  $\mu\text{l}/\text{min}$ , and the total injection volume was controlled by an electrically controlled injector (Baby Bee; Bioanalytical Systems, Inc., West Lafayette, USA). The injection volume was 2.0 or 3.0  $\mu\text{l}$  at each site. The muscimol injection was expected to inactivate striatal neurons located around 2 mm in diameter based on the simultaneous recording of neuronal activity and muscimol injection (Shima and Tanji 1998). Post-injection blocks started 30 min after the injections were completed, because the effects of muscimol on task performance appeared at about 30 min (Shima and Tanji 1998; Sawaguchi and Iba 2001).

## Data analysis

Three types of behavioral parameters were defined: task start time (TST) from illumination of start cue to depression of the start button, reaction time (RT) from onset of GO signal to the release of the start button, and movement time (MT) from the release of the start button to depression of the target button. These parameters served as motor indices. They were quantitatively compared before and after muscimol injection by using ANOVA ( $P < 0.05$ ). To evaluate reward probability-dependent changes of motivation, the correlation coefficients between reward probabilities and TSTs were deemed to be statistically significant at  $P < 0.05$ . Speed of arm movement was evaluated by assessing movement times for each target button.

Choice data were pooled and compared between pre-injection (first and second) blocks and post-injection (third and fourth) blocks by the use of Fisher's exact probability test with the threshold for statistical significance set at  $P < 0.05$ . The effects of muscimol injection on task strategy were evaluated by examining the choices with valid (lose-shift and win-stay) and invalid (lose-stay and win-shift) strategies before and after the injection on N2, N3, and R trials (Fisher's exact probability test,  $P < 0.05$ ). Optimal choices for value-based decision-making were defined as choosing higher-value options among three alternatives. In the N3 trial, the monkeys made one of three types of choices: choice of the button tried at N1 trials (non-optimal), choice of the button tried at N2 trials (non-optimal), and choice of the one remaining button (optimal).

## Histological examination

After all behavioral experiments were completed, small electrolytic lesions were made at 20 locations along 10 selected electrode tracks in the putamen while monkeys were quietly sitting on the primate chair. In many cases, micro-lesions were made at the border between the

putamen and the external segment of the globus pallidus using the neuronal discharge properties as a guide. Direct anodal current (20  $\mu$ A) was passed for 30 s through tungsten microelectrodes. The monkeys were deeply anesthetized with an overdose of pentobarbital sodium (90 mg/kg, i.m.) and perfused with 4% paraformaldehyde in 0.1 M phosphate buffer through the left ventricle. Coronal sections of the striatum, 50  $\mu$ m in thickness, were stained with cresyl violet. The tracks of the microelectrode and injection needle through the putamen were reconstructed on the histology sections using the electrolytic lesion marks as reference points, and the locations of the muscimol and saline injections were identified.

## Results

A total of 17 muscimol injections (10 in monkey TN, 7 in monkey YO) and 9 saline injections (3 in monkey TN, 6 in monkey YO) were made into the putamen of two

hemispheres of two monkeys (Table 1). The locations of all injections are summarized in Fig. 2.


Effects of inactivation of the putamen on motivation to start trials for multi-step choices

We measured TST, as a conventionally used index for motivation to work for reward (Shidara et al. 1998; Watanabe et al. 2001; Lauwereyns et al. 2002; Satoh et al. 2003). Figure 3 plots the TSTs against reward probabilities of individual trial types. The TSTs were negatively correlated with the reward probabilities: shortest at highest probability (R trials) and longest at lowest probability (N1 trials). In both monkey TN and monkey YO, the TSTs after muscimol injection became significantly longer in all trial types than those before injection in the anterior, middle, and posterior levels of the putamen (ANOVA, injection effect, monkey TN: anterior level,  $F_{1,3} = 29.85$ ,  $P < 0.0001$ ; middle level,  $F_{1,3} = 158.0$ ,  $P < 0.0001$ ; posterior level,  $F_{1,3} = 96.24$ ,  $P < 0.0001$ , monkey YO: anterior level,

**Table 1** Summary of the injection sites and effects

Monkey/site		Drug	Volume	Injection number	Distance from AC	Non-optimal choices at N3 trials	MTs at N1 trials
Monkey TN							
Anterior level	a	Muscimol	3 $\mu$ l	1	+3.0 mm	NS	NS
	b	Muscimol	2 $\mu$ l	1	+3.0 mm	NS	NS
	c	Saline	2 $\mu$ l	1	+2.0 mm	NS	NS
Middle level	d	Muscimol	2 $\mu$ l	1	$\pm 0.0$ mm	↑	NS
	e	Muscimol	2 $\mu$ l	1	$\pm 0.0$ mm	NS	↑
	f	Muscimol	3 $\mu$ l	1	-1.0 mm	↑	NS
	g	Muscimol	3 $\mu$ l/2 $\mu$ l	1/1	-2.0 mm	NS/↑	↑/↑
	h	Saline	2 $\mu$ l	1	-2.0 mm	NS	NS
Posterior level	i	Muscimol/Saline	2 $\mu$ l/2 $\mu$ l	1/1	-5.0 mm	NS/NS	NS/NS
	j	Muscimol	2 $\mu$ l	1	-6.0 mm	NS	↑
	k	Muscimol	2 $\mu$ l	1	-6.0 mm	NS	↑
Monkey YO							
Anterior level	l	Saline	2 $\mu$ l	1	+3.0 mm	NS	NS
	m	Muscimol	2 $\mu$ l	1	+3.0 mm	NS	NS
	n	Saline	2 $\mu$ l	1	+3.0 mm	NS	NS
	o	Muscimol	2 $\mu$ l	1	+2.0 mm	NS	NS
Middle level	p	Muscimol	2 $\mu$ l	1	-1.0 mm	↑	↑
	q	Muscimol	2 $\mu$ l	1	-1.0 mm	NS	NS
	r	Saline	2 $\mu$ l	1	-2.0 mm	NS	NS
	s	Muscimol	2 $\mu$ l	1	-2.0 mm	↑	NS
	t	Saline	2 $\mu$ l	1	-2.0 mm	NS	NS
Posterior level	u	Saline	2 $\mu$ l	1	-6.0 mm	NS	NS
	v	Muscimol	2 $\mu$ l	1	-6.0 mm	NS	↑
	w	Muscimol	2 $\mu$ l	1	-6.0 mm	NS	↑
	x	Saline	2 $\mu$ l	1	-7.0 mm	NS	NS


The direction of *arrows* indicates an increase of the value (Fisher's exact probability test). NS, statistically not significant; AC, anterior commissure



**Fig. 2** Sites of injection of muscimol and saline. Sites of individual injections reconstructed from histology in monkey TN (*upper panel*) and YO (*bottom panel*). Symbol sizes indicate injection number (large circle denotes two injections, and small circles, single injection). Filled circles, open circles, and half-filled circle denote the injection sites of muscimol, saline, and muscimol or saline, respectively

$F_{1,3} = 16.52$ ,  $P < 0.0001$ ; middle level,  $F_{1,3} = 119.4$ ,  $P < 0.0001$ ; posterior level,  $F_{1,3} = 16.08$ ,  $P < 0.0001$  (Fig. 3a). Notably, the negative correlation between TSTs and reward probabilities was maintained after muscimol injections for all injection sites. On the other hand, there was no consistent change in TSTs after saline injection (shortening after injection at the middle level of the putamen in monkey TN, lengthening after injection at the anterior and posterior level of monkey YO, and no significant change after the other injections) (Fig. 3b). These results indicate that inactivation of the putamen did not impair the processes of estimation of trial type-specific reward value and of reward value-dependent motivation to start individual choices for reward: i.e., there was a low level of motivation with low reward probability and a high level of motivation with high reward probability.

It would be possible that reaction time would change depending on factors other than motivational level at the



**Fig. 3** Negative correlation between task start time and reward probability for individual choices was maintained after muscimol injection. **a** Plots of task start time against reward probability before and after muscimol injections. The injections were made at the anterior, middle, and posterior level of the putamen in monkey TN (*left column*) and monkey YO (*right column*). **b** Same plots before and after saline injections. Gray lines denote task start times during pre-injection blocks, and black lines denote those during post-injection blocks. Data represent mean  $\pm$  SEM. Regression lines are superimposed


start of trials, such as the number of response options and the number of previous choices necessary to remember and to decide on an optimal choice in current trials. However,

the TST, sum of reaction time and movement time became shorter as the number of previous choices to remember and to decide on an optimal choice increased (Fig. 3). In other words, TST was negatively correlated with number of response options. Thus, among possible factors influencing TST as a function of N1–N3, motivation to work for reward appeared to be the most critical one.

#### Inactivation of putamen impairs reward history-based action selection

Although task strategies (lose-shift and win-stay) were essential components for optimal performance of the task, they were insufficient in the case of N3 trials in which monkeys had chosen small-reward buttons during the last two successive trials. Monkeys had to choose the one remaining button, but not buttons chosen during the N1 or N2 trials. In other words, monkeys chose the highest-value option among three alternatives while updating values of individual options based on the histories of choices and their outcomes. Figure 4 shows the rate of choosing buttons not tried at immediately preceding choices (lose-shift rate) during the search epoch (Fig. 4a), and the rate of choosing the same button as in the last trials (win-stay rate) during the repeat epoch (Fig. 4b). In both of two monkeys, the very high lose-shift and win-stay rates were maintained after muscimol injection (Table 2). Thus, the monkeys could perform the multi-step choice task for rewards based on the lose-shift and win-stay strategy under local inactivation of the putamen.

As shown in the representative results in Fig. 5, the rate of non-optimal, small-reward choices increased selectively at N3 trials after muscimol injection (Fisher's exact probability test,  $P < 0.05$ ). This was observed in both of the monkeys examined. The non-optimal choices occurred by choosing the button that had already been chosen (Fig. 5a, arrows) and resulted in small reward during the N1 trials. Thus, the choices were valid for the lose-shift strategy but were non-optimal for choosing the highest-value option. The rate of non-optimal choices in the N2 and R trials remained very low after muscimol injection (Fig. 5b). An increase in the non-optimal N3 choice rates occurred after muscimol injection in the middle anterior–posterior level of the putamen (Fig. 6a,  $P < 0.05$ , Fisher's exact probability test), whereas no significant change was evident after injections into the anterior and posterior levels (Fig. 2). When monkeys made a non-optimal N3 choice, they kept choosing until they got the large reward. After muscimol injection in the middle anterior–posterior level of the putamen, the large-reward target was reached within two additional trials in 93% of non-optimal N3 choices in Monkey TN (74% in one additional trial) and in 90% in Monkey YO (71% in one additional trial). Thus, the number of N3 trials increased after local inactivation of



**Fig. 4** Inactivation of the putamen did not impair lose-shift and win-stay strategies for multi-step choices. **a** Rate of lose-shift before and after muscimol injections in the anterior, middle, and posterior parts of the putamen in monkeys TN and YO. N1→N2 and N2→N3 indicate lose-shift rate from N1 to N2 trials and from N2 to N3 trials, respectively. **b** The rate of win-stay when the trials were switched from search to repetition trials (R). Error bars represent SEM

the putamen. Once this occurred, there were two or three N3 trials in a row, such as shown in Fig. 5a. Non-optimal choice rates in the N2 and R trials remained very low after each of the 17 muscimol injections (Fig. 6a). The rate of non-optimal choices in the N2, N3, and R trials did not change significantly following injections of physiological saline at any site in the putamen (Fig. 6b). Most of the non-optimal N3 choices occurred when the monkeys chose buttons that were already chosen in the N1 trials (Fig. 5a).


There would be two critically important components of lost functions after putamen inactivation related to the choice of the N1 buttons again during N3 trials. One is the working memory load: monkeys chose a different target from the last one selected (lose-shift) during search choices and the same target (win-stay) during repetition choices by



**Table 2** *P* values for lose-shift and win-stay strategies


	Lose-shift			
	Monkey TN		Monkey YO	
	N1→N2	N2→N3	N1→N2	N2→N3
Anterior level	0.06	0.25	0.21	>0.99
Middle level	0.10	0.46	0.37	0.20
Posterior level	0.05	0.73	0.30	>0.99
	Win-stay			
	Monkey TN		Monkey YO	
	R	R	R	R
Anterior level	>0.99		0.62	
Middle level	0.62		0.27	
Posterior level	0.17		0.08	

*P* values determined using Fisher's exact probability test



**Fig. 5** Inactivation of the putamen at the middle level increases the non-optimal choice rate in N3 trials in the case of muscimol injection (specimen). **a** An example of action selection during the multi-step choice task before and after muscimol injection in monkey TN. Asterisks and arrows denote reward target and non-optimal choice, respectively. Dashed lines denote the end of one trial. L, M, and R denote for left, middle, and right target choice, respectively. **b** Example of changes in non-optimal choice rate in each trial type for monkey TN (left column) and monkey YO (right column). Comparisons were made between pre-injection blocks and post-injection blocks. Broken lines, black lines, and gray lines denote for inappropriate choice rate in N2 trials, N3 trials, and R trials, respectively. \* *P* < 0.05 Fisher's exact probability test between pre- and post-injections

remembering the last choices (Fig. 4). But, in the N3 trials, they had to remember not only the last N2 choice but also the N1 choice. The other was an imperfect value-based choice. Monkeys can choose one reward target among



**Fig. 6** Changes in the non-optimal choice rate for monkey TN (left column) and monkey YO (right column). **a** Muscimol injections. **b** Saline injections. Comparisons were made between pre-injection blocks and post-injection blocks. Broken lines, black lines, and gray lines denote the non-optimal choice rate in N2 trials, N3 trials, and R trials, respectively. Data represent mean ± SEM. \*\* *P* < 0.01 Fisher's exact probability test


three alternatives by updating the values of chosen targets depending on their outcomes: i.e., lowering after small reward and elevating after large reward. But, because working memory would provide knowledge of previously chosen options and their outcomes in the processes of the history-based value update and action selection, inactivation of local activity of the putamen in this study suggests composite functions of the putamen in decision-making and action selection.

### Slowness of movement after inactivation of the putamen at middle and caudal putamen

We examined the effects of inactivation of the putamen on behavioral measures of task performance. Figure 7 shows movement times from release of the start button to depression of the target button during N1 trials. Movement times became longer after muscimol injection in the middle and posterior level of the putamen. The lengthening of movement times occurred for all 3 target buttons (left, middle, and right) (Fig. 7a). However, there was no significant change in movement times after injection in the anterior part of the putamen (Bonferroni correction, monkey TN: left target,  $P = 0.09$ ; middle target,  $P = 0.43$ ; right target,  $P = 0.54$ , monkey YO: left target,  $P = 0.08$ ; middle target,  $P = 0.25$ ; right target,  $P = 0.33$ ). In control experiments with saline injection, there was no lengthening of movement times for any injection site (Fig. 7b). This observation was consistent with the previous results of inactivation of the striatum (Miyachi et al. 1997) and blockade of glutamatergic transmission in the globus pallidus (Kato and Kimura 1992).

### Discussion

In the present study, we found three lines of evidence suggesting critical involvement of the putamen in reward history-based action selection. First, after the putamen was inactivated locally, the monkeys normally changed options if the last choice resulted in small reward (lose-shift) and stayed with the last choice if it was followed by large reward (win-stay). However, the rate of non-optimal choices increased at the third trials following two successive small-reward choices where the monkeys chose an option already tried at the first choice. At the third choices, monkeys had to update values of individual options based on the previously tried two options and their outcomes and to choose highest-value options. Therefore, the specific effects of inactivation suggested pivotal roles of the putamen in reward history-based value update and action selection. On the other hand, although non-optimal choices at N3 trials significantly increased after muscimol injection, the correct choice rate was still considerably higher (74% in monkey TN, 71% in monkey YO) than that of N2 trials (48% in monkey TN, 46% in monkey YO). This was probably due to the fact that inactivation by muscimol injection (2–3  $\mu\text{l}$ , 5  $\mu\text{g}/\mu\text{l}$ ) covered limited areas of the putamen. Second, the effects of inactivation of the putamen on reward history-based action selection were especially strong at the middle rostro-caudal level, but were not significant at the rostral and caudal level. Third, reward value-dependent motivation to work for reward did not appear to be influenced by local inactivation of the putamen.



**Fig. 7** Slow movement of task performance after inactivation of the putamen at the middle and posterior levels. **a** Movement time from release of start button to depression of left (L), middle (M), and right (R) button before and after muscimol injections during N1 trials for monkey TN (left column) and monkey YO (right column). **b** Data for saline injections (same paradigm as in previous panel). Bars graphs represent mean  $\pm$  SEM. \* and \*\*  $P < 0.05$  and  $P < 0.01$  in ANOVA

### Brain circuit for reward history-based action selection and involvement of the striatum

Theories of reinforcement learning describe reward-based decision-making and adaptive choice of actions by estimating how the extent of the rewards a series of actions will yield (value function), and selecting the action by updating and comparing the value function of multiple alternatives based on the reward prediction errors (Sutton and Barto 1998). Midbrain dopaminergic neurons encode errors of reward expectation (Schultz et al. 1997; Satoh et al. 2003; Morris et al. 2004) as well as salience of events and motivation for actions (Redgrave et al. 1999; Satoh et al. 2003; Matsumoto and Hikosaka 2009). The frontal cortex (Matsumoto et al. 2003; Barraclough et al. 2004;

Daw et al. 2006), parietal cortex (Platt and Glimcher 1999; Sugrue et al. 2004), and basal ganglia (Lauwereyns et al. 2002; Samejima et al. 2005; Morris et al. 2006; Lau and Glimcher 2008) have been suggested to play a major part in value-based decision-making and choice behavior.

Neurons in the anterior cingulate cortex (ACC) of monkeys display modulation of activity related to the degree of reward expectancy estimated by previous experiences (Shidara and Richmond 2002) and to the rewards in previous trials (Seo and Lee 2007). Lesions of the ACC in monkeys do not impair reinforcement-guided choices immediately after errors but make the monkeys unable to sustain rewarded responses (Kennerley et al. 2006), suggesting critical involvement of the ACC in integrating information of chosen actions and their outcomes over time for guiding future actions. Lesions of the orbitofrontal cortex caused a deficit in stimulus selection but not action selection based on the previous reward experiences, in contrast with lesions of the ACC (Rudebeck et al. 2008). In our study, inactivation of the middle level of the putamen caused impairment of multi-step choices based on the action and reward history. This was in contrast to the fact that choices guided by a simple strategy of lose-shift and win-stay immediately following the choices remained intact (Fig. 4). Thus, these results support a view that the putamen, especially at the middle rostro-caudal level, plays a vital role in choices based on the action and reward history, which include integration and update of action and reinforcement information over time.

The motivation to work for reward may have declined after inactivation of the putamen, because the lengthening of TSTs was occurred after muscimol injection (Fig. 3). However, the monkeys could control the level of motivation depending on the reward value (probability) of individual choices: i.e., they were highly motivated (short TSTs) when the value of choices was high and vice versa (Fig. 3) after putamen inactivation. This suggested that motivational control of value-based choices is achieved mostly through other cortico-basal ganglia loop circuits, such as those involving the caudate nucleus and ventral striatum. It is unclear whether muscimol-induced lengthening of TSTs without significant change in reaction time to GO signal reflects a selective slowing of internally guided or triggered movements, because both TSTs and reaction time to GO signal are measures of triggered movements.

#### Working memory function

It could be argued that the deficits in reinforcement-guided choices after inactivation of the putamen are attributable to a general failure of working memory, which might compromise recall of the actions and outcomes experienced in previous trials. Although there is a mnemonic component in remembering the history of past actions and outcomes,

the results of previous studies of inactivation of neuronal activity and blockade of dopaminergic functions in the putamen cannot simply be ascribed to deficits in the process of remembering (Monchi et al. 2001; Coull et al. 2008; Kojima et al. 2009; Beck et al. 2010), in contrast with the results of studies in which the lateral prefrontal cortex was lesioned (Fuster 1991; Goldman-Rakic 1996). Vulnerability to working memory overload may be mediated by reduced activity of the prefrontal-limbic system (e.g., amygdala, hippocampus) (Monchi et al. 2001; Yun et al. 2010).

Matching behavior after negative and positive feedback (lose-shift and win-stay) was executed almost perfectly in this study without a significant influence of the putamen inactivation. However, inactivation of the putamen led monkeys to make errors in N3 trials as a result of choosing N1 buttons (Figs. 5, 6). Thus, the most critical functions that were lost after putamen inactivation were consistent with the reward history-based update of values of chosen options for action selection, part of which includes known components of working memory, such as short-term maintenance and manipulation of information (Baddeley and Hitch 1974).

#### Region-specific effects of inactivation on functions of the putamen

In the present study, inactivation at the middle rostro-caudal level of the putamen had a significant effect on choices based on the histories of previous choices and their outcomes. This part of the putamen receives dense projections from the medial frontal cortical areas, especially from part of the ACC that also innervates limbic basal ganglia circuits (McFarland and Haber 2000; Takada et al. 2001; Haber et al. 2006). Consistent with these cortico-striatal projections, accumulating evidence suggests critical involvement of the ACC in integrating information of chosen actions and their outcomes over time for guiding future actions (Kennerley et al. 2006; Rudebeck et al. 2008). The caudal region of the putamen receives projections predominantly from motor-related cortical areas (Flaherty and Graybiel 1995; McFarland and Haber 2000; Nambu et al. 2002). Inactivation of the middle and caudal part of the putamen induced slower movement in task performance (Fig. 7a), which is consistent with the predominant projections from motor and somatosensory cortical areas. Inactivation of the major target of the putamen, the globus pallidus, influences the kinematics of task movement (Kato and Kimura 1992; Desmurget and Turner 2008; Desmurget and Turner 2010).

Although a total of 17 locations of muscimol injection covered wide areas of the putamen in two monkeys, the effects of inactivation were still limited to the relatively

dorsal part of the putamen and the ventral part was not examined (Fig. 2). Thus, the present study did not necessarily test all possible functions of the putamen, but focused on reward-based evaluation and selection of actions. This was because recent studies on the striatum emphasize evaluative functions such as representation of values of actions and stimuli and outcomes (Kawagoe et al. 1998; Samejima et al. 2005; Lau and Glimcher 2003; Hori et al. 2009). Involvement of the limbic cortico-basal ganglia circuits through the ventral striatum is also suggested in reward-based action selection (Cardinal and Howes 2005; McCoy and Platt 2005; Nicola 2007; Ito and Doya 2009). Processing of values for decision and action selection in the putamen, caudate nucleus, and ventral striatum appear to depend on the value-specific inputs from wide cortical areas (Haber et al. 2006) and from midbrain dopaminergic neurons (Haber and Knutson 2010). Thus, the involvement of the putamen in reward history-based action selection which we found in this study seems to reflect a common aspect of the basic functions of the striatum and cortico-basal ganglia system, such as proposed by reinforcement learning models of the basal ganglia in value of actions are encoded in the striate projection neurons and updated by dopamine-mediated prediction error signals to select a series of actions expected to maximize rewards (Houk et al. 1995; Schultz et al. 1997; Sutton and Barto 1998; Doya 2000; O'Doherty et al. 2004).

**Acknowledgments** This research was supported by a Grant-in-Aid for Scientific Research on Priority Areas, and “Development of biomarker candidates for social behavior” from the Ministry of Education, Culture, Sports, Science, and Technology, MEXT Japan (M.K.).

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

## References

- Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. *Annu Rev Neurosci* 9:357–381
- Ashby FG, Turner BO, Horvitz JC (2010) Cortical and basal ganglia contributions to habit learning and automaticity. *Trends Cogn Sci* 14:208–215
- Baddeley AD, Hitch GJL (1974) Working Memory. In: Bower GA (ed) *The psychology of learning and motivation: advances in research and theory vol 8*. Academic Press, New York, pp 47–89
- Balleine BW, O'Doherty JP (2010) Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. *Neuropsychopharmacology* 35:48–69
- Barracough DJ, Conroy ML, Lee D (2004) Prefrontal cortex and decision making in a mixed-strategy game. *Nat Neurosci* 7:404–410
- Beck SM, Locke HS, Savine AC, Jimura K, Braver TS (2010) Primary and secondary rewards differentially modulate neural activity dynamics during working memory. *PLoS One* 5:e9251
- Cardinal RN, Howes NJ (2005) Effects of lesions of the nucleus accumbens core on choice between small certain rewards and large uncertain rewards in rats. *BMC Neurosci* 6:37
- Corbit LH, Janak PH (2010) Posterior dorsomedial striatum is critical for both selective instrumental and Pavlovian reward learning. *Eur J Neurosci* 31:1312–1321
- Coull JT, Nazarian B, Vidal F (2008) Timing, storage, and comparison of stimulus duration engage discrete anatomical components of a perceptual timing network. *J Cogn Neurosci* 20:2185–2197
- Daw ND, O'Doherty JP, Dayan P, Seymour B, Dolan RJ (2006) Cortical substrates for exploratory decisions in humans. *Nature* 441:876–879
- DeLong MR, Alexander GE, Mitchell SJ, Richardson RT (1986) The contribution of basal ganglia to limb control. *Prog Brain Res* 64:161–174
- Desmurget M, Turner RS (2008) Testing basal ganglia motor functions through reversible inactivations in the posterior internal globus pallidus. *J Neurophysiol* 99:1057–1076
- Desmurget M, Turner RS (2010) Motor sequences and the basal ganglia: kinematics, not habits. *J Neurosci* 30:7685–7690
- Doya K (2000) Complementary roles of basal ganglia and cerebellum in learning and motor control. *Curr Opin Neurobiol* 10:732–739
- Fiorillo CD, Tobler PN, Schultz W (2003) Discrete coding of reward probability and uncertainty by dopamine neurons. *Science* 299:1898–1902
- Flaherty AW, Graybiel AM (1995) Motor and somatosensory corticostriatal projection magnifications in the squirrel monkey. *J Neurophysiol* 74:2638–2648
- Fuster JM (1991) The prefrontal cortex and its relation to behavior. *Prog Brain Res* 87:201–211
- Goldman-Rakic PS (1996) The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. *Philos Trans R Soc Lond B Biol Sci* 351:1445–1453
- Graybiel AM (2008) Habits, rituals, and the evaluative brain. *Annu Rev Neurosci* 31:359–387
- Haber SN, Knutson B (2010) The reward circuit: linking primate anatomy and human imaging. *Neuropsychopharmacology* 35:4–26
- Haber SN, Kim KS, Maily P, Calzavara R (2006) Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning. *J Neurosci* 26:8368–8376
- Hikosaka O, Takikawa Y, Kawagoe R (2000) Role of the basal ganglia in the control of purposive saccadic eye movements. *Physiol Rev* 80:953–978
- Hikosaka O, Nakamura K, Nakahara H (2006) Basal ganglia orient eyes to reward. *J Neurophysiol* 95:567–584
- Hollerman JR, Schultz W (1998) Dopamine neurons report an error in the temporal prediction of reward during learning. *Nat Neurosci* 1:304–309
- Hori Y, Minamimoto T, Kimura M (2009) Neuronal encoding of reward value and direction of actions in the primate putamen. *J Neurophysiol* 102:3530–3543
- Houk JC, Adams JL, Barto AG (1995) A model of how the basal ganglia generate and use neural signals that predict reinforcement. In: Houk JC, Davis JL, Beiser DG (eds) *Models of information processing in the basal ganglia*. The MIT Press, Cambridge, pp 249–270
- Inokawa H, Yamada H, Matsumoto N, Muranishi M, Kimura M (2010) Juxtacellular labeling of tonically active neurons and phasically active neurons in the rat striatum. *Neuroscience* 168:395–404

- Ito M, Doya K (2009) Validation of decision-making models and analysis of decision variables in the rat basal ganglia. *J Neurosci* 29:9861–9874
- Kato M, Kimura M (1992) Effects of reversible blockade of basal ganglia on a voluntary arm movement. *J Neurophysiol* 68:1516–1534
- Kawagoe R, Takikawa Y, Hikosaka O (1998) Expectation of reward modulates cognitive signals in the basal ganglia. *Nat Neurosci* 1:411–416
- Kennerley SW, Walton ME, Behrens TE, Buckley MJ, Rushworth MF (2006) Optimal decision making and the anterior cingulate cortex. *Nat Neurosci* 9:940–947
- Kimura M, Minamimoto T, Matsumoto N, Hori Y (2004) Monitoring and switching of cortico-basal ganglia loop functions by the thalamo-striatal system. *Neurosci Res* 48:355–360
- Kojima T, Onoe H, Hikosaka K, Tsutsui K, Tsukada H, Watanabe M (2009) Default mode of brain activity demonstrated by positron emission tomography imaging in awake monkeys: higher rest-related than working memory-related activity in medial cortical areas. *J Neurosci* 29:14463–14471
- Lau B, Glimcher PW (2008) Value representations in the primate caudate nucleus during matching behavior. *Neuron* 58:451–463
- Lauwereyns J, Watanabe K, Coe B, Hikosaka O (2002) A neural correlate of response bias in monkey caudate nucleus. *Nature* 418:413–417
- Matsumoto M, Hikosaka O (2009) Two types of dopamine neuron distinctly convey positive and negative motivational signals. *Nature* 459:837–841
- Matsumoto K, Suzuki W, Tanaka K (2003) Neuronal correlates of goal-based motor selection in the prefrontal cortex. *Science* 301:229–232
- McCoy AN, Platt ML (2005) Expectations and outcomes: decision-making in the primate brain. *J Comp Physiol A Neuroethol Sens Neural Behav Physiol* 191:201–211
- McFarland NR, Haber SN (2000) Convergent inputs from thalamic motor nuclei and frontal cortical areas to the dorsal striatum in the primate. *J Neurosci* 20:3798–3813
- Middleton FA, Strick PL (2000) Basal ganglia and cerebellar loops: motor and cognitive circuits. *Brain Res Brain Res Rev* 31:236–250
- Miyachi S, Hikosaka O, Miyashita K, Karadi Z, Rand MK (1997) Differential roles of monkey striatum in learning of sequential hand movement. *Exp Brain Res* 115:1–5
- Monchi O, Petrides M, Petre V, Worsley K, Dagher A (2001) Wisconsin card sorting revisited: distinct neural circuits participating in different stages of the task identified by event-related functional magnetic resonance imaging. *J Neurosci* 21:7733–7741
- Morris G, Arkadir D, Nevet A, Vaadia E, Bergman H (2004) Coincident but distinct messages of midbrain dopamine and striatal tonically active neurons. *Neuron* 43:133–143
- Morris G, Nevet A, Arkadir D, Vaadia E, Bergman H (2006) Midbrain dopamine neurons encode decisions for future action. *Nat Neurosci* 9:1057–1063
- Nambu A (2008) Seven problems on the basal ganglia. *Curr Opin Neurobiol* 18:595–604
- Nambu A, Kaneda K, Tokuno H, Takada M (2002) Organization of corticostriatal motor inputs in monkey putamen. *J Neurophysiol* 88:1830–1842
- Nicola SM (2007) The nucleus accumbens as part of a basal ganglia action selection circuit. *Psychopharmacology (Berl)* 191:521–550
- O’Doherty J, Dayan P, Schultz J, Deichmann R, Friston K, Dolan RJ (2004) Dissociable roles of ventral and dorsal striatum in instrumental conditioning. *Science* 304:452–454
- Pasquereau B, Nadjar A, Arkadir D, Bezaud E, Goillandeau M, Bioulac B, Gross CE, Boraud T (2007) Shaping of motor responses by incentive values through the basal ganglia. *J Neurosci* 27:1176–1183
- Platt ML, Glimcher PW (1999) Neural correlates of decision variables in parietal cortex. *Nature* 400:233–238
- Redgrave P, Prescott TJ, Gurney K (1999) Is the short-latency dopamine response too short to signal reward error? *Trends Neurosci* 22:146–151
- Rudebeck PH, Behrens TE, Kennerley SW, Baxter MG, Buckley MJ, Walton ME, Rushworth MF (2008) Frontal cortex subregions play distinct roles in choices between actions and stimuli. *J Neurosci* 28:13775–13785
- Samejima K, Ueda Y, Doya K, Kimura M (2005) Representation of action-specific reward values in the striatum. *Science* 310:1337–1340
- Satoh T, Nakai S, Sato T, Kimura M (2003) Correlated coding of motivation and outcome of decision by dopamine neurons. *J Neurosci* 23:9913–9923
- Sawaguchi T, Iba M (2001) Prefrontal cortical representation of visuospatial working memory in monkeys examined by local inactivation with muscimol. *J Neurophysiol* 86:2041–2053
- Schultz W, Dayan P, Montague PR (1997) A neural substrate of prediction and reward. *Science* 275:1593–1599
- Seo H, Lee D (2007) Temporal filtering of reward signals in the dorsal anterior cingulate cortex during a mixed-strategy game. *J Neurosci* 27:8366–8377
- Shidara M, Richmond BJ (2002) Anterior cingulate: single neuronal signals related to degree of reward expectancy. *Science* 296:1709–1711
- Shidara M, Aigner TG, Richmond BJ (1998) Neuronal signals in the monkey ventral striatum related to progress through a predictable series of trials. *J Neurosci* 18:2613–2625
- Shima K, Tanji J (1998) Both supplementary and pre supplementary motor areas are crucial for the temporal organization of multiple movements. *J Neurophysiol* 80:3247–3260
- Sugrue LP, Corrado GS, Newsome WT (2004) Matching behavior and the representation of value in the parietal cortex. *Science* 304:1782–1787
- Sutton RS, Barto AG (1998) Reinforcement learning. The MIT press, Cambridge
- Takada M, Tokuno H, Hamada I, Inase M, Ito Y, Imanishi M, Hasegawa N, Akazawa T, Hatanaka N, Nambu A (2001) Organization of inputs from cingulate motor areas to basal ganglia in macaque monkey. *Eur J Neurosci* 14:1633–1650
- Tricomi E, Balleine BW, O’Doherty JP (2009) A specific role for posterior dorsolateral striatum in human habit learning. *Eur J Neurosci* 29:2225–2232
- Watanabe M, Cromwell HC, Tremblay L, Hollerman JR, Hikosaka K, Schultz W (2001) Behavioral reactions reflecting differential reward expectations in monkeys. *Exp Brain Res* 140:511–518
- Yamada H, Matsumoto N, Kimura M (2004) Tonically active neurons in the primate caudate nucleus and putamen differentially encode instructed motivational outcomes of action. *J Neurosci* 24:3500–3510
- Yun RJ, Krystal JH, Mathalon DH (2010) Working memory overload: fronto-limbic interactions and effects on subsequent working memory function. *Brain Imaging Behav* 4:96–108

# A New Mitochondria-Related Disease Showing Myopathy with Episodic Hyper-creatine Kinase-emia

Yuji Okamoto, MD, PhD,<sup>1</sup> Itsuro Higuchi, MD,<sup>1</sup> Yusuke Sakiyama, MD,<sup>1</sup>  
Shoko Tokunaga, MD,<sup>1</sup> Osamu Watanabe, MD, PhD,<sup>1</sup> Kimiyoshi Arimura, MD,<sup>2</sup>  
Masanori Nakagawa, MD,<sup>3</sup> and Hiroshi Takashima, MD, PhD<sup>1</sup>

**Objective:** To elucidate the relationship between mitochondrial DNA (mtDNA) alterations and a mitochondrial disease with a distinct combination of characteristic symptoms, namely episodic hyper-creatine kinase (CK)-emia and mild myopathy.

**Methods:** We selected 9 patients with mtDNA np8291 alteration from 586 patients suspected to have a mitochondrial disease, and assessed them clinically, pathologically, and genetically. These 9 patients had undiagnosed mitochondrial myopathy with episodic hyper-CK-emia, all showing similar symptoms and progression.

**Results:** Patients had mild muscle weakness and episodic hyper-CK-emia triggered by infections or drugs. Five of 9 patients were initially diagnosed with other conditions, such as myasthenia gravis, polymyositis, viral myositis, and drug-induced myopathy, because these conditions were acute or subacute, and 9 patients showed the same 16 mtDNA alterations, which have been reported to be nonpathological polymorphisms. Muscle biopsy revealed ragged-red fibers, highly expressed succinate dehydrogenase staining fibers, and cytochrome c oxidase-deficient fibers. Because their mitochondrial sequence data was almost the same, and 9 patients live in widely separated cities in Japan, the alterations may have arisen from a single source.

**Interpretation:** These findings suggest that mild myopathy with episodic hyper-CK-emia associated with some of the 16 mtDNA alterations or at least with their mitochondria, could be a novel mitochondrial disease. Therefore, we propose that this disease be named as "mitochondrial myopathy with episodic hyper-CK-emia (MIMECK)." These alterations could work concomitantly and probably modify the impact of medications or other environmental factors. We believe these findings provide an insight into a novel aspect of mitochondrial disease pathogenesis.

ANN NEUROL 2011;70:486–492

Persistently high blood creatine kinase (CK) levels are a hallmark of neuromuscular disease.<sup>1</sup> Serum CK levels show a variable increase in several systemic conditions such as genetic myopathy, viral infections, connective tissue disorders, electrolyte imbalance, and endocrine dysfunction.<sup>2</sup> Idiopathic hyper-CK-emia presents as persistently high serum CK levels with normal neurological, neurophysiological, and neuropathological findings.<sup>3</sup> Persistent asymptomatic hyper-CK-emia progresses to mild or early-stage myopathy in many cases.<sup>4</sup> Furthermore, numerous drugs are reportedly myotoxic. A prospective study on patients from a university hospital revealed 171 cases with high CK levels, the drugs primarily responsible being sta-

tins (46.4%), fibrates (14.3%), antiretrovirals (14.3%), and angiotensin-II receptor antagonists (10.7%).<sup>5</sup> Although the mechanisms of drug-induced muscle damage are unclear, an association between mitochondrial function and drug-induced myopathy has been reported.<sup>6–9</sup>

We experienced 9 distinct cases of mitochondrial myopathy in patients with episodic hyper-CK-emia, and diagnosed these as mitochondrial disease. Mitochondrial myopathies usually affect multiple organs and exhibit a broad spectrum of disorders. Numerous mutations and polymorphisms have been reported in the mitochondrial DNA (mtDNA) database (MITOMAP: human mitochondrial genome database; <http://www.mitomap.org>).<sup>10</sup>

View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com). DOI: 10.1002/ana.22498

Received Jan 9, 2011, and in revised form May 11, 2011. Accepted for publication May 27, 2011.

Address correspondence to Dr Takashima, Professor and Chairman, Department of Neurology and Geriatrics, Kagoshima University, Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima 890-8520, Japan. E-mail: [thiroshi@m3.kufm.kagoshima-u.ac.jp](mailto:thiroshi@m3.kufm.kagoshima-u.ac.jp)

From the <sup>1</sup>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; <sup>2</sup>Okatsu Neurology and Rehabilitation Hospital, Kagoshima, Japan; <sup>3</sup>Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Over 150 point mutations and innumerable large-scale rearrangements are associated with mitochondrial diseases, which are heterogeneous disorders with a myriad of clinical features.<sup>11</sup> However, neither idiopathic hyper-CK-emia associated with mitochondrial dysfunction nor disease-causing mitochondrial mutations in drug-induced mitochondrial myopathy have been reported. Here we report a novel mitochondrial disease with a distinct combination of characteristic symptoms, namely episodic hyper-CK-emia and mild myopathy. We discuss the relation between mtDNA alterations and this disease.

## Patients and Methods

### Patients

We studied 586 patients who were referred to our department from South Kyushu (Kagoshima, Miyazaki, Oita, and Okinawa Prefectures), southern Japan, from 1992 to 2009. These patients included those diagnosed with or suspected of having mitochondrial disease—such as mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke (MELAS); myoclonic epilepsy and ragged-red fiber (RRF) disease (MERRF); chronic progressive external ophthalmoplegia (CPEO)—or were patients without a definitive diagnosis. Previously, we reported adult-onset mitochondrial myopathy (4 patients included in this study) with a mtDNA np8291 A-to-G substitution.<sup>12</sup> However, the pathogenesis of this disorder is unclear because np8291 is a noncoding nucleotide located 4 bases before the 5' end of transfer RNA (tRNA) (*Lys*). At our institution, an mtDNA np8291 is usually determined by screening patients diagnosed with or suspected of having mitochondrial disease because this alteration is located near np8344, which is the typical MERRF mutation.<sup>13</sup> We focused on this rare alteration and selected only 9 patients (8 families) with mtDNA np8291 alteration from the abovementioned 586 patients; these 9 patients had undiagnosed mitochondrial myopathy with episodic hyper-CK-emia based on clinical findings, all showing similar symptoms and progression. We reassessed these 9 patients clinically, pathologically, and genetically to identify the features of this disease. These 9 patients lived in widely separated cities in the southern part of Japan.

All patients had been referred by their primary physicians or neurologists. Signed, informed consent was obtained for every patient. The Institutional Review Board of Kagoshima University approved this study.

### Histopathological Study

All muscle biopsies were obtained from the biceps brachii or quadriceps femoris muscles. The specimens were immediately frozen in isopentane and cooled with liquid nitrogen. Frozen sections (thickness, 8  $\mu$ m) were stained with hematoxylin-eosin, modified Gomori trichrome (mGT), succinate dehydrogenase (SDH), cytochrome *c* oxidase (CCO), periodic acid-Schiff, Sudan black, myosin adenosine triphosphatase (ATPase), and reduced nicotinamide adenine dinucleotide (NADH)-tetrazolium reductase.

### mtDNA Analysis

Genomic DNA was extracted from peripheral blood leukocytes and muscles using the Puregene Blood Core Kit C (Qiagen, Tokyo, Japan) or the DNeasy Blood and Tissue kit (Qiagen). MitoChip v2.0 was obtained from Affymetrix (commercially available GeneChip Human Mitochondrial Resequencing array 2.0; Tokyo, Japan). mtDNA from all lymphocyte and skeletal muscle samples were analyzed on separate chips. The entire mtDNA sequence was amplified in 3 overlapping polymerase chain reactions (PCRs) using 50ng genomic DNA in each reaction.<sup>14</sup> Reagents, conditions, and purification were accomplished as described in previous reports.<sup>15</sup> Pooling, DNA fragmentation, labeling, and chip hybridization were performed as per Affymetrix Customseq Resequencing protocol instructions. The chips were washed on the Affymetrix fluidics station using Customseq Resequencing wash protocols. Microarray data for MitoChips v2.0 were analyzed using GeneChip Sequence Analysis Software v4.0 (Affymetrix).<sup>16</sup> We also confirmed key alterations (np8291). In brief, 50ng of the patient's genomic DNA was amplified using a hot-start PCR method and a forward (5'-CATGCCCATCGTCCTAGAA) and reverse primer (5'-TTTGGTGAGGGAGGTAAGTG).<sup>17</sup> PCR products were generated under the following conditions: 15 minutes at 95°C, 42 cycles of amplification (95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute), and 30 minutes at 72°C.

Using a presequencing kit (USB, Cleveland, OH), we purified patients' PCR products and sequenced them with dye-terminator chemistry using an ABI377 automated sequencer (Applied Biosystems, Tokyo, Japan). We aligned the resulting sequences and evaluated mutations and alterations using the Sequencher sequence alignment program (Gene Codes, Ann Arbor, MI).

## Results

### Clinical Features

We present the case histories of only 3 among the 9 patients in detail, because all 9 patients had similar clinical features (Table 1).

**CASE 1.** This 71-year-old woman had a significant family history. Her sister had previously reported similar symptoms but was not included in this study. Our patient noticed slight muscle weakness at the age of 40 years, and by her late 60s she often felt lethargic. At the age of 70 years, general weakness, dysphagia, and dysarthria appeared several weeks after a bout of common cold. She was initially diagnosed with myasthenia gravis, but the symptoms were resolved almost completely without medication upon admission. Her serum CK level increased transiently up to 360IU/liter (normal range, 45–163IU/liter). She exhibited mild proximal dominant muscle weakness, and hypothyroidism was detected after admission.

**CASE 2.** This 57-year-old woman had reported muscle weakness and an inability to run fast while still in school. By the age of 40 years, she was experiencing limb

TABLE 1: Clinical Characteristics of Mitochondrial Myopathy Patients with Episodic Hyper-CK-emia

Case	Age/Sex	Onset (yr)	CK (Usual) (IU/liter)	CK (Episodic) (IU/liter)	Subacute Onset	Dysphagia	Myalgia	Muscle Weakness	RRF (%)	SDH (%)	CCO (%)	Trigger	Initial Diagnosis
1	71/F	69	150	360	+	+	-	Mild	1.5	3	2	Common cold	MG
2	57/F	41	100	617	+	-	+	Mild	1	2.5	2	Common cold	Viral myositis
3	64/M	62	181	593	+	+	+	Mild	1.5	2	2.5	Lamivudine	Drug-induced myopathy
4	59/F	54	180	209	-	-	-	Mild	4	6	8	-	-
5	71/M	65	270	11708	+	+	+	Moderate	2.5	8.5	7	-	PM
6	50/F	47	98	985	+	+	+	Mild	2	3	2.5	-	PM
7	70/F	50	67	527	-	-	+	Mild	4	7.5	3	-	-
8	38/M	35	328	1478	+	-	+	Moderate	4	6	5.5	-	-
9	42/F	39	200	1089	-	-	-	Mild	2	5	5	-	-

Serum CK levels during the course of the disease are indicated in 2 columns: (1) usual condition and (2) maximum episodic value (normal range 45-163 IU/liter). Trigger indicates the event-precipitating symptoms. CCO = cytochrome c oxidase-deficient fibers; CK = creatine kinase; F = female; M = male; MG = myasthenia gravis; PM = polymyositis; RRF = ragged-red fibers; SDH = highly expressed succinate dehydrogenase staining fibers.

myalgia with every bout of common cold. She exhibited proximal dominant muscle weakness and elevated serum CK levels (691U/liter) upon admission. Thereafter, she gradually developed mild proximal dominant muscle weakness, but her serum CK level normalized. Although easily fatigued, she could manage day-to-day activities without support. Her 29-year-old daughter (data not shown) showed no evidence of muscle weakness; however, she complained of tiredness and exhibited an elevated serum CK level (more than 1,000U/liter).

**CASE 3.** This 64-year-old man was a chronic hepatitis B patient. By the age of 62 years, he had gradually developed dysarthria and dysphagia following lamivudine treatment for hepatitis B. However, he did not complain of limb weakness. Laboratory examination revealed normal blood lactate and pyruvate levels (9.8mg/dl and 0.8mg/dl, respectively), elevated lactate and normal pyruvate levels in the cerebrospinal fluid (21.4mg/dl and 1.0mg/dl, respectively), and an elevated serum CK level of 593U/liter. We initially suspected drug-induced myopathy. After discontinuing lamivudine, several symptoms improved slightly but dysphagia persisted.

We present a summary of patient characteristics and clinical findings in Table 1. The patient age ranged from 38 to 71 years, with the age of onset ranging from 30 to 60 years. All 9 patients had mild or moderate muscle weakness. Four of the 9 patients had a relevant clinical family history, and Case 7 was the mother of Case 8. Mild muscle weakness was observed in 7 patients. Varying serum CK levels were observed, and 5 of the 9 patients were initially diagnosed in other hospitals with other conditions, such as myasthenia gravis, polymyositis, viral myositis, and drug-induced myopathy. The mode of onset in 6 patients was acute or subacute. Seven patients experienced dysphagia or myalgia. Elevation in serum CK levels and myalgia resolved after lamivudine was discontinued.


**Histopathological Study**

Muscle biopsies from all patients indicated myopathic changes. Histopathological studies revealed a moderate variation in muscle fiber size but no necrotic fibers. Several RRFs (1-4%) were detected in all mGT-stained samples. Highly expressed fibers (2.0-8.5%) were observed in SDH-stained samples, but strongly SDH-reactive blood vessels were not detected in any sample. CCO-deficient fibers (2%-8%) were detected in all samples (Fig).

**mtDNA Analysis**

Sequencing of the entire mtDNA of 9 patients revealed the same 16 alterations: np200, np257, np1442, np4612, np5127, np6332, np7389, 9bp deletion between np8281 and 8289, np8291, np10403, np11151, np11969,





**FIGURE 1:** Histochemical results following muscle biopsy. Numbers correspond to case index identifiers. (A) Typical ragged-red fibers (1–4%) were detected in all Gomori trichrome-stained samples. (B) Highly expressed fibers were observed (2–8.5%) in succinate dehydrogenase-stained samples. (C) Cytochrome c oxidase-deficient fibers (2–8%) were detected in all samples. Bar = 100 $\mu$ m.

np13105, np16325, np16390, and np16523 (Table 2). All patients had the same 16 polymorphisms. In addition, Patient 4 had 3 additional mtDNA alterations (np3834, np4718, and np7375). These 16 mtDNA alterations have previously been reported as nonpathological polymorphisms. Six substitutions caused coding polymorphisms; other substitutions were observed in the 12S ribosomal RNA, a hypervariable site, and the displacement loop (D-loop). The mtDNA transition at np8291 has been reported and was considered to be a rare polymorphism. The frequency of mtDNA transition at np8291 was detected in only 2 of 600 controls (0.3%), including healthy subjects and patients with other neuromuscular disorders. Two positive patients had diabetes mellitus or myotonic dystrophy.<sup>12</sup> We could not detect any mtDNA alteration as a disease-associated mutation. The sequencing results of lymphocyte and skeletal muscle mtDNA were identical. All mtDNA variants in all patients were homoplasmic mtDNA alterations.

## Discussion

We describe patients with novel mitochondrial myopathy characterized by episodic muscle weakness and elevated

serum CK levels triggered by infections, drugs, or stressful situations. Furthermore, we demonstrate an association between mtDNA alterations, thus providing a novel aspect of mitochondrial disease pathogenesis.

Five of the 9 patients were initially diagnosed with other diseases, such as myasthenia gravis, polymyositis, viral myositis, or drug-induced myopathy. Disease onset was acute or subacute, and the patients experienced dysphagia or myalgia when on medication or during a bout of common cold. Case 3, an index case of this study, was admitted to the hospital following gradual development of dysarthria and dysphagia after lamivudine treatment for chronic hepatitis B. Initially, we suspected drug-induced myopathy because several symptoms, apart from dysphagia, were slightly improved after lamivudine was discontinued.

Mitochondrial dysfunction is a well-known side effect of nucleoside analogs, the best-known example being zidovudine, which is used mainly to manage human immunodeficiency virus infections.<sup>18</sup> In zidovudine-induced myopathy, molecular analysis of muscle biopsy shows depletion of mtDNA caused by drug-induced inhibition of mtDNA polymerase  $\gamma$ .<sup>19</sup> Following the muscle biopsy report of Case 3 that revealed RRFs, highly expressed

**TABLE 2: Total mtDNA Sequencing Identified 16 Alterations Previously Reported as Polymorphisms, 10 Alterations in the MITOMAP Database, and 9 in the GiiB-JST mtSNP Database**

Gene Product	Nucleotide Number	Base Change	Amino Acid Change	MITOMAP Database	GiiB-JST mtSNP Database
Hypervariable segment 2	200	A to G		Reported polymorphism	
Hypervariable segment 2	257	A to G		Reported polymorphism	Reported polymorphism
12S ribosomal RNA	1442	G to A			Reported polymorphism
NADH dehydrogenase 2	4612	T to C	M to T		Reported polymorphism
NADH dehydrogenase 2	5127	A to G	N to D		Reported polymorphism
Cytochrome <i>c</i> oxidase 1	6332	A to G	Synonymous		
Cytochrome <i>c</i> oxidase 1	7389	C to T	Y to H	Reported polymorphism	
Noncoding nucleotides 7	8272	9bp deletion		Reported polymorphism	
Noncoding nucleotides 7	8291	A to G		Reported polymorphism	Reported polymorphism
NADH dehydrogenase 3	10403	A to G	Synonymous	Reported polymorphism	Reported polymorphism
NADH dehydrogenase 4	11151	C to T	A to V	Reported polymorphism	
NADH dehydrogenase 4	11969	G to A	A to T	Reported polymorphism	
NADH dehydrogenase 5	13105	A to G	I to V	Reported polymorphism	Reported polymorphism
D-loop	16325	T to G			Reported polymorphism
D-loop	16390	G to A		Reported polymorphism	
D-loop	16523	A to G			Reported polymorphism

D-loop = displacement loop; GiiB-JST mtSNP = human mitochondrial genome single nucleotide polymorphism database (<http://mitsnp.tnig.or.jp/mitsnp/index.shtml>); MITOMAP = human mitochondrial genome database (<http://www.mitomap.org>); mtDNA = mitochondrial DNA; NADH = reduced nicotinamide adenine dinucleotide.

SDH staining fibers, and CCO-deficient fibers, this case was diagnosed with mitochondrial myopathy.

Muscle biopsy from the other patients revealed several RRFs, highly expressed SDH staining fibers, and CCO-deficient fibers. Histochemical parameters showed relatively mild alterations, and the low frequency of CCO-deficient fibers and RRFs might have been influenced by age-related changes. However, we could not explain the histochemical findings in Cases 8 and 9 as age-related changes because these were younger patients; hence, we

surmise that their histochemical findings could be associated with their clinical features and the pathogenetic property of mtDNA alterations. Accordingly, we diagnosed all 9 cases as mitochondrial disease of similar genetic background and clinical findings.

Six patients in this study had experienced severe myalgia at some point in time; this is characteristic of recurrent myoglobinuria associated with mtDNA mutation.<sup>20-22</sup> In contrast, elevated serum CK levels were relatively low in these patients and recurrence rates were also

low; no patient had a history of voiding dark brown urine or acute renal failure. Furthermore, serum CK levels had normalized without medication at follow-up examinations. We believe that mild muscle weakness and the minor, episodic elevation in CK levels observed in our patients could be caused by mitochondrial dysfunction, as indicated by histochemical findings.

Patients in this study originated from 8 different families, but they had the same 16 mtDNA polymorphisms and a similar phenotype. In addition, all patients originated from the southern part of Japan. These results suggest that this disease is of mitochondrial origin, caused by mtDNA alterations, and transmitted by maternal inheritance, leading to the possibility that a common source exists or had existed in southern Japan. At the same time, these mitochondrial diseases were less likely to be associated with nuclear DNA. We evaluated all mtDNA alterations listed in MITOMAP and GiiB-JST (human mitochondrial genome single nucleotide polymorphism database; <http://mitsnp.tmg.or.jp/mitsnp/index.shtml>), the largest publicly available compendium of mtDNA polymorphisms. We found the following 16 alterations: np200, np257, np1442, np4612, np5127, np6332, np7389, 9bp deletion between np8281 and 8289, np8291, np10403, np11151, np11969, np13105, np16325, np16390, and np16523. However, each alteration previously reported in MITOMAP and GiiB-JST had been described as a nonpathological alteration.

The 16 polymorphisms are probably because of a rare haplotype that is probably derived from the B4f1 haplogroup of the East Asian mtDNA haplogroups that share 14 of the 16 polymorphisms (np200, np257, np1442, np4612, np5127, np6332, np7289, 9bp deletion between np8281 and 8289, np8291, np11969, np13105, np16325, np16390, and np16523).<sup>23</sup>

In addition, oxidative phosphorylation complex activity was studied in a previous study that included 4 of the 9 patients from this study; the activity of complex IV relative to that of citrate synthetase was reduced to about 50% in normal controls in this previous study.<sup>12</sup> Mitochondrial disease is usually caused by a pathological mtDNA rearrangement, with mtDNA mutations being classified as depletion, deletion/duplication, and point mutations. Nevertheless, a previous study reported that retrospective screening of 2,000 patients suspected of mtDNA disorders for common point mutations and large deletions identified mutations in only 6% of the patient population.<sup>24</sup> Mitochondrial myopathies with isolated skeletal muscle involvement and mtDNA mutation are relatively rare. However, many patients could live normally with pure myopathy but still harbor unknown

genetic defects in the mtDNA. A previous study reported exercise intolerance due to mutations in the cytochrome *b* gene of mtDNA;<sup>25</sup> the clinical manifestations included progressive exercise intolerance, proximal limb weakness, and in some cases, myoglobinuria.

In several reports, double disease-associated mutations were detected in the same patients with Leber's hereditary optic neuropathy (LHON);<sup>26–28</sup> these mutations may have some influence on the symptoms of LHON. Another study reported that some polymorphisms adjacent to the 3243A>G mutation had different effects on the clinical phenotype, muscle pathology, and respiratory chain enzyme activity.<sup>29</sup> Yet another pathogenesis has been suggested; antiretroviral therapy causes peripheral neuropathy, a pathogenesis in which nucleoside reverse transcriptase inhibitor (NRTI)-associated mitochondrial dysfunction, inflammation, and nutritional factors have been implicated. Owing to its well-documented potential for inducing mitochondrial dysfunction and oxidative stress, NRTI therapy could be considered as a significant environmental challenge, which, when superimposed on genetic susceptibility, leads to a toxicity phenotype. The environmentally determined genetic expression (EDGE) concept provides a framework for considering the combinations of genetic and environmental exposure that define the thresholds for expression of specific phenotypes in an individual. This concept holds that genetic variations in expressed proteins have different effects in different environmental contexts, and that disease or toxicity phenotype is determined by the functional magnitude of the genetic change and the severity of the environmental exposure.<sup>30</sup>

In summary, the findings of distinct clinical features, mitochondrial pathologic changes and the same mitochondrial genetic background in all patients suggest that this disease could be a novel mitochondrial disease. Although we did not identify the key pathogenic mutations, this disease should be associated with some of the 16 mtDNA alterations or at least with their mitochondria. Therefore, we propose that this disease be named as "mitochondrial myopathy with episodic hyper-CK-emia (MIMECK)." We believe that this study provides an insight into a novel aspect of mitochondrial disease pathogenesis.

Furthermore, pharmacogenetic studies on drug-induced and associated mtDNA alterations could contribute to research leading to the discovery and design of novel drugs that would eliminate the negative side effects associated with current therapies. Further genetic and clinical studies, especially involving persons of another race and from other geographic areas, will clarify the pathogenesis of this disease.

## Acknowledgments

This research was supported by grants from the Nervous and Mental Disorders and Research Committee for Ataxic Disease of the Japanese Ministry of Health, Welfare and Labor (19A-1 to H.T.); the Ministry of Education, Culture, Sports, Science, and Technology of Japan (21591095 to H.T.; 21591094 to I.H.); and the Nervous and Mental Disorders from the Ministry of Health, Labor, and Welfare (20B-13 to I.H.).

We thank Ms. A. Yoshimura and Ms. N. Hirata of our department for their excellent technical assistance.

## Potential Conflict of Interest

I.H. received grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (grant 21591094), and the Nervous and Mental Disorders from the Ministry of Health, Labor, and Welfare (grant 20B-13). H.T. received grants from the Nervous and Mental Disorders and Research Committee for Ataxic Disease of the Japanese Ministry of Health, Welfare and Labor (grant 19A-1) and the Ministry of Education, Culture, Sports, Science, and Technology of Japan (grant 21591095). H.T. has received research grants or speaking fees from Eisai, Pfizer, Sanofi-Aventis, Teijin Pharma, Novartis, Tanabe-Mitsubishi Dainippon-Sumitomo, Astellas, GlaxoSmithkline and Benesis.

## References

- Munsat TL, Baloh R, Pearson CM, Fowler W. Serum enzyme alterations in neuromuscular disorders. *JAMA* 1973;226:1536–1543.
- Hays AP, Gamboa ET. Acute viral myositis. In: Engel AG, Franzini Armstrong C, eds. *Myology: basic and clinical*. Vol 2. 2nd ed. New York: McGraw-Hill, 1994;1399–1418.
- Rowland LP, Willner J, Di Mauro S, Miranda A. Approaches to the membrane theory of Duchenne muscular dystrophy. In: Angelini C, Danielli GA, Fontanri D, eds. *Muscular dystrophy—advances and new trends*. Amsterdam: Excerpta Medica, 1980;3–13.
- Joy JL, Oh SJ. Asymptomatic hyper-CK-emia: an electrophysiologic and histopathologic study. *Muscle Nerve* 1989;12:206–209.
- Dogue A, Bagheri H. Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals. *Eur J Clin Pharmacol* 2004;60:285–292.
- Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. *Clin Invest Med* 2001;24:258–272.
- Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? *Drug Saf* 2002;25:649–663.
- Thompson PD, Clarkson P. Statin-associated myopathy. *JAMA* 2003;289:1681–1690.
- Dalakas MC. Peripheral neuropathy and antiretroviral drugs. *J Peripher. Nerv Syst* 2001;6:14–20.
- Brandon MC, Lott MT, Nguyen KC, et al. MITOMAP: a human mitochondrial genome database—2004 update. *Nucl Acids Res* 2005;33:D611–D613.
- Dimauro S. Mitochondrial DNA and disease. *Ann Med* 2005;37:222–232.
- Hirata K, Nakagawa M, Higuchi I, et al. Adult onset limb-girdle type mitochondrial myopathy with a mitochondrial DNA np8291 A-to-G substitution. *J Hum Genet* 1999;44:210–214.
- Shoffner JM, Lott MT, Lezza AM, et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. *Cell* 1990;61:931–937.
- Maitra A, Cohen Y, Gillespie SE, et al. The human mitochip: a high-throughput sequencing microarray for mitochondrial mutation detection. *Genome Res* 2004;14:812–819.
- Zhou S, Kassaei K, Cutler DJ, et al. An oligonucleotide microarray for high-throughput sequencing of the mitochondrial genome. *J Mol Diagn* 2006;8:476–482.
- Cutler DJ, Zwick ME, Carraquillo MM, et al. High throughput validation detection and genotyping using microarrays. *Genome Res* 2001;11:1913–1925.
- Boerkoel CF, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. *Am J Hum Genet* 2001;68:325–333.
- Chariot P, Gherardi R. Myopathy and HIV infections. *Curr Opin Rheumatol* 1995;7:497–502.
- Masanés F, Barrientos A, Cebrian M, et al. Clinical, histological and molecular reversibility of zidovudine myopathy. *J Neurol Sci* 1998;159:226–228.
- Ohno K, Tanaka M, Sahashi T, et al. Mitochondrial DNA deletions in inherited recurrent myoglobinuria. *Ann Neurol* 1991;29:364–369.
- Melberg A, Holme E, Oldfors A, Lundberg PO. Rhabdomyolysis in autosomal dominant progressive external ophthalmoplegia. *Neurology* 1998;50:299–300.
- Karadimas CL, Greenstein P, Sue CM, et al. Recurrent myoglobinuria due to a nonsense mutation in the COX I gene of mitochondrial DNA. *Neurology* 2000;55:644–649.
- Kong QP, Bandelt HJ, Sun C, et al. Updating the East Asian mtDNA phylogeny: a prerequisite for the identification of pathogenic mutations. *Hum Mol Genet* 2006;15:2076–2086.
- Liang MH, Wong L-JC. Yield of mtDNA mutations analysis in 2000 patients. *Am J Med Genet* 1998;77:385–400.
- Andreu AL, Hanna MG, Reichmann H, et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. *N Engl J Med* 1999;341:1037–1044.
- Mimaki M, Ikota A, Sato A, et al. A double mutation (G11778A and G12192A) in mitochondrial DNA associated with Leber's hereditary optic neuropathy and cardiomyopathy. *J Hum Genet* 2003;48:47–50.
- Brown MD, Torroni A, Reckford CL, Wallace DC. Phylogenetic analysis of Leber's hereditary optic neuropathy mitochondrial DNA indicates multiple independent occurrences of the common mutations. *Hum Mutat* 1995;6:311–325.
- Riodan-Eva P, Sanders MD, Govan GG, et al. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenetic mitochondrial DNA mutation. *Brain* 1995;118:319–337.
- Mimaki M, Hatakeyama H, Ichiyama T, et al. Different effects of novel mtDNA G3242A and G3244A base changes adjacent to a common A3243G mutation in patients with mitochondrial disorders. *Mitochondrion* 2009;9:115–122.
- Kallianpur AR, Hulgan T. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. *Pharmacogenomics* 2009;10:623–627.